articleTop 1% cited

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial

Annals of Neurology · 2009 · Vol. 66(4) · pp. 460–471

Kathleen Hawker✉(The Ohio State University Wexner Medical Center)Paul O’Connor(University of Toronto)Mark S. Freedman(Ottawa Hospital)Peter A. CalabresiJack P. Antel(McGill University)Jack H. Simon(Portland VA Medical Center)Stephen L. Hauser(University of California, San Francisco)Emmanuelle Waubant(University of California, San Francisco)Timothy Vollmer(University of Colorado Denver)Hillel Panitch(University of Vermont)Jiameng ZhangPeter ChinCraig H. SmithOLYMPUS trial group

View via DOI Publisher page

Abstract

Although time to CDP between groups was not significant, overall subgroup analyses suggest selective B-cell depletion may affect disease progression in younger patients, particularly those with inflammatory lesions.

Multiple Sclerosis Research Studies Immunotherapy and Immune Responses Polyomavirus and related diseasesRituximabMedicinePlaceboClinical endpointInternal medicineRandomizationMultiple sclerosisGastroenterologyAdverse effectExpanded Disability Status Scale

MeSH terms

RituximabAdolescentAdultAgedAntibodies, MonoclonalDouble-Blind MethodFemaleHumansInfusions, IntravenousMaleMiddle AgedDisease ProgressionMultiple Sclerosis, Chronic ProgressiveYoung AdultAntibodies, Monoclonal, Murine-Derived

Citations

928

FWCI

29.51

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria